EE04639B1 - Raku adhesiooni pärssiv ühend ja seda sisaldav farmatseutiline kompositsioon - Google Patents

Raku adhesiooni pärssiv ühend ja seda sisaldav farmatseutiline kompositsioon

Info

Publication number
EE04639B1
EE04639B1 EEP200000698A EEP200000698A EE04639B1 EE 04639 B1 EE04639 B1 EE 04639B1 EE P200000698 A EEP200000698 A EE P200000698A EE P200000698 A EEP200000698 A EE P200000698A EE 04639 B1 EE04639 B1 EE 04639B1
Authority
EE
Estonia
Prior art keywords
cell adhesion
pharmaceutical composition
inhibiting compound
adhesion inhibiting
cell
Prior art date
Application number
EEP200000698A
Other languages
English (en)
Estonian (et)
Inventor
Lee Wen-Cherng
Gill Alan
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200000698A publication Critical patent/EE200000698A/xx
Publication of EE04639B1 publication Critical patent/EE04639B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000698A 1998-05-28 1999-05-28 Raku adhesiooni pärssiv ühend ja seda sisaldav farmatseutiline kompositsioon EE04639B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8706498P 1998-05-28 1998-05-28
PCT/US1999/011924 WO1999061421A1 (en) 1998-05-28 1999-05-28 A NOVEL VLA-4 INHIBITOR: oMePUPA-V

Publications (2)

Publication Number Publication Date
EE200000698A EE200000698A (et) 2002-06-17
EE04639B1 true EE04639B1 (et) 2006-06-15

Family

ID=22202907

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000698A EE04639B1 (et) 1998-05-28 1999-05-28 Raku adhesiooni pärssiv ühend ja seda sisaldav farmatseutiline kompositsioon

Country Status (31)

Country Link
US (1) US6495525B1 (xx)
EP (1) EP1082302B1 (xx)
JP (1) JP2002516309A (xx)
KR (1) KR100636713B1 (xx)
CN (1) CN1148350C (xx)
AT (1) ATE256659T1 (xx)
AU (1) AU764108B2 (xx)
BG (1) BG65021B1 (xx)
CA (1) CA2333656C (xx)
CZ (1) CZ298413B6 (xx)
DE (1) DE69913687T2 (xx)
DK (1) DK1082302T3 (xx)
EA (1) EA002988B1 (xx)
EE (1) EE04639B1 (xx)
ES (1) ES2211096T3 (xx)
HK (1) HK1035726A1 (xx)
HU (1) HUP0102255A3 (xx)
IL (1) IL139967A (xx)
IS (1) IS5737A (xx)
MX (1) MXPA00011774A (xx)
NO (1) NO317990B1 (xx)
NZ (1) NZ509199A (xx)
PL (1) PL198189B1 (xx)
PT (1) PT1082302E (xx)
SI (1) SI1082302T1 (xx)
SK (1) SK285280B6 (xx)
TR (1) TR200100190T2 (xx)
UA (1) UA65623C2 (xx)
WO (1) WO1999061421A1 (xx)
YU (1) YU75500A (xx)
ZA (1) ZA200007300B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
JP2001524465A (ja) * 1997-11-24 2001-12-04 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害剤としての置換β−アラニン誘導体
AU757873B2 (en) * 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CZ2002518A3 (cs) 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
NZ518886A (en) 1999-12-28 2004-02-27 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2002053534A1 (fr) 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs de vla-4
ES2382806T3 (es) 2003-07-24 2012-06-13 Daiichi Sankyo Company, Limited Compuesto ácido ciclohexanocarboxílico
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US7685367B2 (en) * 2006-03-08 2010-03-23 Microsoft Corporation Multi-cache cooperation for response output caching
MX2009001272A (es) * 2006-08-02 2009-02-11 Genzyme Corp Terapia de combinacion.
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
EP3466977B1 (en) 2010-04-16 2022-01-05 Biogen MA Inc. Anti-vla-4 antibodies
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1149971B (it) 1979-06-11 1986-12-10 Syntex Inc Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en) 1985-01-23 1988-02-16 Abbott Laboratories Functionalized peptidylaminoalcohols
US4826815A (en) 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
DK163689A (da) 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
DK0506748T3 (da) 1989-12-22 1996-01-22 Commw Scient Ind Res Org Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
CA2043741C (en) 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co Inc Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5352667A (en) 1991-11-22 1994-10-04 Ofer Lider Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them
WO1993012809A1 (en) 1991-12-24 1993-07-08 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de) 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en) 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
JPH08505628A (ja) 1993-01-08 1996-06-18 田辺製薬株式会社 ペプチド型細胞接着阻害薬
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
US5922755A (en) 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
PL190866B1 (pl) * 1996-07-25 2006-02-28 Biogen Inhibitor adhezji komórek, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania

Also Published As

Publication number Publication date
BG105060A (en) 2001-08-31
PL198189B1 (pl) 2008-06-30
EA002988B1 (ru) 2002-12-26
UA65623C2 (en) 2004-04-15
SK285280B6 (sk) 2006-10-05
HK1035726A1 (en) 2001-12-07
EA200001236A1 (ru) 2001-06-25
CN1148350C (zh) 2004-05-05
ZA200007300B (en) 2002-02-27
CN1307561A (zh) 2001-08-08
CZ298413B6 (cs) 2007-09-26
HUP0102255A2 (hu) 2001-11-28
NO20006023L (no) 2001-01-17
IL139967A (en) 2005-11-20
ES2211096T3 (es) 2004-07-01
CA2333656C (en) 2008-07-29
ATE256659T1 (de) 2004-01-15
TR200100190T2 (tr) 2001-05-21
EP1082302B1 (en) 2003-12-17
WO1999061421A1 (en) 1999-12-02
IL139967A0 (en) 2002-02-10
DE69913687T2 (de) 2004-10-07
PL344440A1 (en) 2001-11-05
IS5737A (is) 2000-11-28
BG65021B1 (bg) 2006-12-29
US6495525B1 (en) 2002-12-17
NO317990B1 (no) 2005-01-17
AU764108B2 (en) 2003-08-07
SK18102000A3 (sk) 2001-07-10
DE69913687D1 (de) 2004-01-29
NO20006023D0 (no) 2000-11-28
PT1082302E (pt) 2004-04-30
KR100636713B1 (ko) 2006-10-20
HUP0102255A3 (en) 2001-12-28
MXPA00011774A (es) 2002-10-17
YU75500A (sh) 2002-12-10
EE200000698A (et) 2002-06-17
AU4219299A (en) 1999-12-13
NZ509199A (en) 2003-10-31
KR20010043906A (ko) 2001-05-25
CZ20004425A3 (en) 2001-05-16
DK1082302T3 (da) 2004-04-26
CA2333656A1 (en) 1999-12-02
SI1082302T1 (en) 2004-06-30
JP2002516309A (ja) 2002-06-04
EP1082302A1 (en) 2001-03-14

Similar Documents

Publication Publication Date Title
EE04639B1 (et) Raku adhesiooni pärssiv ühend ja seda sisaldav farmatseutiline kompositsioon
BR9908280A (pt) Inibidores de enzimas de fosfolipase
HUP0201214A2 (en) Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
DK0966465T3 (da) Inhibitorer af IMPDH-enzymer
EE200000488A (et) Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
EP1315500A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TOPICAL ADMINISTRATION OF CYCLOOXYGENASE-2 INHIBITORS
EP0374440A3 (en) Inhibitors of lysyl oxidase
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
HUP0304084A3 (en) Dipeptide derivatives having an terminal 2-thioacyl group as vasopeptidase inhibitors and pharmaceutical compositions containing them
GEP20063956B (en) Cell adhesion inhibitors
AU3413100A (en) Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase
AU2360995A (en) Methionine sulfone and s-substituted cysteine sulfone derivatives as enzyme inhibitors
RO117913B1 (ro) Derivaţi de n-[(amino-(imino)metil)fenil]propil amide substituite, compoziţie farmaceutică care îi conţine şi metodă de tratament
EE200200530A (et) Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid
RS90904A (xx) Nova so perindoprila i farmaceutske kompozicije koje sadrže tu so
MA26492A1 (fr) Inhibiteurs de proteases nouveaux et compositions pharmaceutiques les contenant .
WO2002028829A3 (en) Peptide deformylase inhibitors
HUP0202401A3 (en) Five-membered heterocyclic amidinec as prodrugs of thrombin inhibitors, pharmaceutical compositions comprising thereof and their use
HUP0101899A3 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use
AU2003271811A1 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
DZ2976A1 (fr) Inhibiteurs de protéases nouveaux, procédé pour leur préparation et compositions pharmaceutiques lescontenant.
AU3183801A (en) Product comprising a heterotrimeric G protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
MY140504A (en) Statin-mmp inhibitor combinations

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090528